Millions Around World To Observe Rare Disease Day PDF Print E-mail
Saturday, 19 February 2011 08:20
Millions Around World To Observe Rare Disease Day
The Relief Foundation will be joining the National Organization for Rare Disorders (NORD) and others around the world in observing World Rare Disease Day on February 28, 2011.  On this day, millions of patients and their families will share their stories to focus a spotlight on rare diseases as an important global public health concern.
“There are nearly 30 million Americans—and millions more around the world—affected by rare diseases,” said Peter L. Saltonstall, president and CEO of NORD.  “Everyone knows someone with a rare disease.  But, while many of these diseases are serious and lifelong, most have no treatment and many are not even being studied by researchers.  Insurance cost for treatment of rare diseases is very expensive and cost prohibitive.  Also, payments for the treatment of rare diseases is often denied by most insurance plans which leaves patients and families without hope for a better future.”
A rare disease is one that affects fewer than 200,000 Americans.  There are nearly 7,000 such diseases affecting nearly 30 million Americans.
World Rare Disease Day was launched in Europe four years ago and last year was observed in 46 nations.  It is always observed on the last day of February.  On that day, patients and patient organizations will post stories, videos and blogs online and host events to raise awareness of these diseases, which are often called “orphans”.
The Relief Foundation represents patients and families affected by Scleroderma.  Scleroderma (skleer-oh-DUR-muh) comes from two Greek words: “sclero” meaning hard, and “derma” meaning skin.  Scleroderma is a chronic autoimmune disorder which means the body's tissues are attacked by its own immune system.  In the simplest of terms, Scleroderma is an overproduction of collagen that can result in thickening or tightening of skin and scarring of internal organs.
Scleroderma is rare and it is estimated by several sources that about 300,000 Americans suffer from this debilitating disease.  Although it’s more common in women between the ages of 25 and 55, the disease also occurs in men and children.  The cause of Scleroderma is unknown and it affects people of all races and ethnic groups.
The Relief Foundation was founded out of a need to provide access to information, tools and people who can bolster the quality of life for individuals living with Scleroderma. Thus, our mission is to be a resource and support organization dedicated to promoting public awareness and providing Relief to people living with Scleroderma and their families.
The Relief Foundation awareness event will be hosted by Lew Prince and Vintage Vinyl at 6610 Delmar Blvd, St. Louis, MO  63130 on Rare Disease Day between 11:00am–1:00pm.  The event will include poster displays, the distribution of fliers, RDD merchandise give-a-ways, a raffle and culminating with a balloon release.
In the U.S., the coalition supporting Rare Disease Day includes patient organizations and advocacy groups, medial professionals and associations, government agencies, researchers, and companies developing treatments for rare diseases.
For more information contact:
Kelly J. Ellison, The Relief Foundation
Founder and President
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.relief-foundation.org
314-497-0040
or visit www.rarediseaseday.us. for information about Rare Disease Day events in the U.S.
The Relief Foundation will be joining the National Organization for Rare Disorders (NORD) and others around the world in observing World Rare Disease Day on February 28, 2011.  On this day, millions of patients and their families will share their stories to focus a spotlight on rare diseases as an important global public health concern.

“There are nearly 30 million Americans—and millions more around the world—affected by rare diseases,” said Peter L. Saltonstall, president and CEO of NORD.  “Everyone knows someone with a rare disease. But, while many of these diseases are serious and lifelong, most have no treatment and many are not even being studied by researchers.  Insurance cost for treatment of rare diseases is very expensive and cost prohibitive.  Also, payments for the treatment of rare diseases is often denied by most insurance plans which leaves patients and families without hope for a better future.”

A rare disease is one that affects fewer than 200,000 Americans.  There are nearly 7,000 such diseases affecting nearly 30 million Americans.

World Rare Disease Day was launched in Europe four years ago and last year was observed in 46 nations.  It is always observed on the last day of February.  On that day, patients and patient organizations will post stories, videos and blogs online and host events to raise awareness of these diseases, which are often called “orphans”.

The Relief Foundation represents patients and families affected by Scleroderma.  Scleroderma (skleer-oh-DUR-muh) comes from two Greek words: “sclero” meaning hard, and “derma” meaning skin.  Scleroderma is a chronic autoimmune disorder which means the body's tissues are attacked by its own immune system.  In the simplest of terms, Scleroderma is an overproduction of collagen that can result in thickening or tightening of skin and scarring of internal organs. 

Scleroderma is rare and it is estimated by several sources that about 300,000 Americans suffer from this debilitating disease.  Although it’s more common in women between the ages of 25 and 55, the disease also occurs in men and children.  The cause of Scleroderma is unknown and it affects people of all races and ethnic groups.

The Relief Foundation was founded out of a need to provide access to information, tools and people who can bolster the quality of life for individuals living with Scleroderma. Thus, our mission is to be a resource and support organization dedicated to promoting public awareness and providing Relief to people living with Scleroderma and their families.

The Relief Foundation awareness event will be hosted by Lew Prince and Vintage Vinyl at 6610 Delmar Blvd, St. Louis, MO  63130 on Rare Disease Day between 11:00am–1:00pm.  The event will include poster displays, the distribution of fliers, RDD merchandise give-a-ways, a raffle and culminating with a balloon release.

In the U.S., the coalition supporting Rare Disease Day includes patient organizations and advocacy groups, medial professionals and associations, government agencies, researchers, and companies developing treatments for rare diseases.
For more information contact:
 
Kelly J. Ellison, The Relief Foundation
Founder and President
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.relief-foundation.org
314-497-0040
or visit www.rarediseaseday.us. for information about Rare Disease Day events in the U.S.

 
More articles :

» The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

Marta Baleva and Krasimir NikolovReceived 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in scleroderma is...

» Pathogenesis and Therapeutic Approaches for Improved Topical Treatment in Localized Scleroderma and Systemic Sclerosis

I. Badea; M. Taylor; A. Rosenberg; M. FoldvariPosted: 09/03/2009; Rheumatology. 2009;48(3):213-221. © 2009 Oxford University PressSSc is a chronic progressive disorder of unknown aetiology characterized by excess synthesis and deposition of...

» Scleroderma Patients At Greater Risk Of Myocardial Infarction Within First Year

According to the first large population-based cohort study of its kind, patients with Systemic Sclerosis or were found to be at a greater than eightfold increased risk of having an acute (MI) during their first year after diagnosis. After that...

» The Clinical Relevance of Autoantibodies in Scleroderma

Khanh T Ho and John D ReveillePublished: 12 February 2003Arthritis Res Ther 2003, 5:80-93 (DOI 10.1186/ar628)© 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)Scleroderma (systemic sclerosis) is associated with several...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...